{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:29:09Z","timestamp":1792272549306,"version":"4.4.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["22GYB05"],"award-info":[{"award-number":["22GYB05"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e30955","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T03:28:01Z","timestamp":1715311681000},"page":"e30955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022"],"prefix":"10.1016","volume":"10","author":[{"given":"Junyi","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9661-4975","authenticated-orcid":false,"given":"Chunyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ajcp\/105.5.589","article-title":"Cytokine function: a study in biologic diversity","volume":"105","author":"Cohen","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1152\/physrev.2003.83.3.835","article-title":"Regulation of wound healing by growth factors and cytokines","volume":"83","author":"Werner","year":"2003","journal-title":"Physiol. Rev."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30955_bib3","first-page":"967","article-title":"Cytokines and hemostasis","volume":"85","author":"Grignani","year":"2000","journal-title":"Haematologica"},{"issue":"9255","key":"10.1016\/j.heliyon.2024.e30955_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow?","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e30955_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm-definition, causes, and implications","volume":"23","author":"Jarczak","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e30955_bib7","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1 Pt 2","key":"10.1016\/j.heliyon.2024.e30955_bib8","first-page":"1216","article-title":"Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1, Transplant","volume":"25","author":"Ferrara","year":"1993","journal-title":"SAVE Proc."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/22221751.2021.1884503","article-title":"COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue","volume":"10","author":"Yongzhi","year":"2021","journal-title":"Emerg. Microb. Infect."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e30955_bib10","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30955_bib11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/acn3.51348","article-title":"Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy","volume":"8","author":"Pensato","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib12","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30955_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.it.2021.06.001","article-title":"The 'cytokine storm': molecular mechanisms and therapeutic prospects","volume":"42","author":"Karki","year":"2021","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2019.02.005","article-title":"Plcgamma2\/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome","volume":"100","author":"Mahajan","year":"2019","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30955_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14787210.2021.1915129","article-title":"Cytokine storm associated coagulation complications in COVID-19 patients: pathogenesis and Management","volume":"19","author":"Savla","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.chest.2018.10.022","article-title":"Lung repair and regeneration in ARDS: role of PECAM1 and Wnt signaling","volume":"155","author":"Villar","year":"2019","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ajem.2007.10.031","article-title":"The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome","volume":"26","author":"Wang","year":"2008","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.heliyon.2024.e30955_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fcimb.2018.00204","article-title":"Leptospirosis pathophysiology: into the storm of cytokines","volume":"8","author":"Cagliero","year":"2018","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102375","article-title":"Ebola virus disease: an emerging and re-emerging viral threat","volume":"106","author":"Rojas","year":"2020","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.heliyon.2024.e30955_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling cytokine storm is vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib22","article-title":"Influenza infection, SARS, MERS and COVID-19: cytokine storm - the common denominator and the lessons to be learned, Clin","volume":"223","author":"Ryabkova","year":"2021","journal-title":"Immunol."},{"issue":"7548","key":"10.1016\/j.heliyon.2024.e30955_bib23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/520429a","article-title":"Bibliometrics: the leiden manifesto for research metrics","volume":"520","author":"Hicks","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/S40037-021-00695-4","article-title":"Bibliometrics: methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect. Med. Educ."},{"key":"10.1016\/j.heliyon.2024.e30955_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7991031","article-title":"Worldwide research trends on diabetic foot ulcers (2004-2020): suggestions for researchers","volume":"2022","author":"Deng","year":"2022","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.heliyon.2024.e30955_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840956","article-title":"A bibliometric and knowledge-map analysis of CAR-T cells from 2009 to 2021","volume":"13","author":"Miao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1035151","article-title":"Uncovering the information immunology journals transmitted for COVID-19: a bibliometric and visualization analysis","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib28","article-title":"Antimicrobial stewardship in surgery: a literature bibliometric analysis","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Public Health"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216135","article-title":"Worldwide research trends on aristolochic acids (1957-2017): suggestions for researchers","volume":"14","author":"Zhou","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e30955_bib30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.euroneuro.2013.01.006","article-title":"International comparative performance of mental health research, 1980-2011","volume":"23","author":"Lariviere","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"10.1016\/j.heliyon.2024.e30955_bib33","article-title":"Research trends in ulcerative colitis: a bibliometric and visualized study from 2011 to 2021","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/asi.22968","article-title":"Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis","volume":"65","author":"Chen","year":"2014","journal-title":"J. Ass. Inf. Sci. Technol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib35","article-title":"Knowledge domain and emerging trends in ferroptosis research: a bibliometric and knowledge-map analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e30955_bib36","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e30955_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib38","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.heliyon.2024.e30955_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859972","article-title":"Structural and temporal dynamics of mesenchymal stem cells in liver diseases from 2001 to 2021: a bibliometric analysis","volume":"13","author":"Shao","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fphar.2020.01169","article-title":"Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention","volume":"11","author":"Hussman","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib42","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl. Sci. Rev."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib43","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the ;Cytokine Storm' in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Infect."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/joim.13144","article-title":"Cytokine storm syndrome in coronavirus disease 2019: a narrative review","volume":"289","author":"Gao","year":"2021","journal-title":"J. Intern. Med."},{"issue":"10223","key":"10.1016\/j.heliyon.2024.e30955_bib45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2020.09.009","article-title":"Compartmental immunophenotyping in COVID-19 ARDS: a case series","volume":"147","author":"Ronit","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib47","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1164\/rccm.202005-1583OC","article-title":"Characterization of the inflammatory response to severe COVID-19 illness","volume":"202","author":"McElvaney","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30955_bib48","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib49","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/infdis\/jiaa363","article-title":"Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China","volume":"222","author":"Chi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e30955_bib50","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cytogfr.2020.12.005","article-title":"The cytokine storm in COVID-19: further advances in our understanding the role of specific chemokines involved","volume":"58","author":"Coperchini","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s10020-020-00230-x","article-title":"IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19","volume":"26","author":"Chen","year":"2020","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10229","key":"10.1016\/j.heliyon.2024.e30955_bib54","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30955_bib55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.gendis.2020.06.009","article-title":"Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome","volume":"7","author":"Lin","year":"2020","journal-title":"Genes Dis"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10753-020-01337-3","article-title":"Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications","volume":"44","author":"Iwasaki","year":"2021","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib57","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2176","article-title":"Covid-19 and kidney injury: pathophysiology and molecular mechanisms","volume":"31","author":"Ahmadian","year":"2021","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tschope","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30955_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"Guo","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.heliyon.2024.e30955_bib60","article-title":"Intestinal damage in COVID-19: SARS-CoV-2 infection and intestinal thrombosis","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib61","first-page":"760","article-title":"COVID-19 and indirect liver injury: a narrative synthesis of the evidence","volume":"9","author":"Idalsoaga","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib62","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s12035-020-02249-x","article-title":"Impact of COVID-19 in the mental health in elderly: psychological and biological updates","volume":"58","author":"Grolli","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100761","article-title":"Coagulation and anticoagulation in COVID-19","volume":"47","author":"Hadid","year":"2021","journal-title":"Blood Rev."},{"key":"10.1016\/j.heliyon.2024.e30955_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100745","article-title":"Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system","volume":"46","author":"Lazzaroni","year":"2021","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30955_bib65","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"McGonagle","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30955_bib66","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jth.14981","article-title":"COVID-19: a collision of complement, coagulation and inflammatory pathways","volume":"18","author":"Chauhan","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30955_bib67","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamaneurol.2020.2065","article-title":"Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review","volume":"77","author":"Zubair","year":"2020","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib68","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib69","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e30955_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953502","article-title":"Low baseline IFN-\u03b3 response could predict hospitalization in COVID-19 patients","volume":"13","author":"Cremoni","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib71","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30955_bib72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12291-021-00989-8","article-title":"Interleukin-6 perpetrator of the COVID-19 cytokine storm","volume":"36","author":"Shekhawat","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.heliyon.2024.e30955_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib74","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s13054-020-03120-0","article-title":"Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19","volume":"24","author":"Ni","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.heliyon.2024.e30955_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155151","article-title":"COVID-19 cytokine storm: the anger of inflammation","volume":"133","author":"Mahmudpour","year":"2020","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30955_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/v13091715","article-title":"SARS-CoV-2 infection modulates ACE2 function and subsequent inflammatory responses in swabs and plasma of COVID-19 patients","volume":"13","author":"Guti\u00e9rrez-Chamorro","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e08957","article-title":"Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery","volume":"8","author":"Mortaz","year":"2022","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib78","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03730-2020","article-title":"Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences","volume":"57","author":"Patel","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.heliyon.2024.e30955_bib79","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.26633\/RPSP.2020.72","article-title":"Ferritin levels and COVID-19","volume":"44","author":"Vargas-Vargas","year":"2020","journal-title":"Rev. Panam. Salud Publica"},{"key":"10.1016\/j.heliyon.2024.e30955_bib80","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cca.2020.06.033","article-title":"Hyperferritinemia in critically ill COVID-19 patients - is ferritin the product of inflammation or a pathogenic mediator?","volume":"509","author":"G\u00f3mez-Pastora","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.heliyon.2024.e30955_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745515","article-title":"Basic predictive risk factors for cytokine storms in COVID-19 patients","volume":"12","author":"Shcherbak","year":"2021","journal-title":"Front. Immunol."},{"issue":"10229","key":"10.1016\/j.heliyon.2024.e30955_bib82","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/00325481.2021.1990091","article-title":"Ferritin as prognostic marker in COVID-19: the FerVid study","volume":"134","author":"Para","year":"2022","journal-title":"Postgrad. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056464","article-title":"Clinicodemographic profile and predictors of poor outcome in hospitalised COVID-19 patients: a single-centre, retrospective cohort study from India","volume":"12","author":"Tiwari","year":"2022","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib85","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.4103\/jfmpc.jfmpc_1921_21","article-title":"Association of serum ferritin with COVID-19 in a cross-sectional study of 200 intensive care unit patients in a rural hospital: is ferritin the forgotten biomarker of mortality in severe COVID-19?","volume":"11","author":"Hulkoti","year":"2022","journal-title":"J Family Med Prim Care"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253894","article-title":"Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis","volume":"16","author":"Melo","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib87","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2020-218323","article-title":"Preliminary predictive criteria for COVID-19 cytokine storm","volume":"80","author":"Caricchio","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e30955_bib89","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids--new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e30955_bib90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"issue":"355","key":"10.1016\/j.heliyon.2024.e30955_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib92","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2024.e30955_bib93","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"32","key":"10.1016\/j.heliyon.2024.e30955_bib94","doi-asserted-by":"crossref","first-page":"18951","DOI":"10.1073\/pnas.2009017117","article-title":"Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19","volume":"117","author":"Cauchois","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib95","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s13054-020-03364-w","article-title":"Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study","volume":"24","author":"Kooistra","year":"2020","journal-title":"Crit. Care"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e30955_bib96","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e30955_bib97","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","article-title":"Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome","volume":"15","author":"Kotch","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063059","article-title":"Therapeutic role of tocilizumab in SARS-CoV-2-induced cytokine storm: rationale and current evidence","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12967-020-02573-9","article-title":"Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial","volume":"18","author":"Perrone","year":"2020","journal-title":"J. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e30955_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2020-218243","article-title":"Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study","volume":"80","author":"Potere","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e30955_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2210","article-title":"Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm","volume":"31","author":"Clark","year":"2021","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib102","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib103","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028555","article-title":"Responses to cytokines and interferons that depend upon JAKs and STATs","volume":"10","author":"Stark","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e30955_bib104","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib106","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/82741","article-title":"Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte","volume":"1","author":"Hotchkiss","year":"2000","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031849","article-title":"Mechanism of caspase-1 inhibition by four anti-inflammatory drugs used in COVID-19 treatment","volume":"23","author":"Caruso","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e30955_bib108","first-page":"1153","article-title":"Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment","volume":"6","author":"Chen","year":"2020","journal-title":"Engineering (Beijing)"},{"issue":"10223","key":"10.1016\/j.heliyon.2024.e30955_bib109","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e30955_bib111","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10787-022-00987-z","article-title":"COVID-19 and corticosteroids: a narrative review","volume":"30","author":"El-Saber Batiha","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib112","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jinf.2020.03.062","article-title":"The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis","volume":"81","author":"Yang","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.heliyon.2024.e30955_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2021.03.002","article-title":"COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome?","volume":"232","author":"Ombrello","year":"2021","journal-title":"Transl. Res."},{"issue":"10285","key":"10.1016\/j.heliyon.2024.e30955_bib114","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Group","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e30955_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102999","article-title":"Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: a prospective cohort study","volume":"60","author":"Masi\u00e1","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e30955_bib116","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.heliyon.2024.e30955_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108517","article-title":"Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment","volume":"218","author":"Yeleswaram","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e30955_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.825749","article-title":"Tocilizumab and COVID-19: timing of administration and efficacy","volume":"13","author":"Abidi","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e30955_bib119","doi-asserted-by":"crossref","first-page":"294","DOI":"10.31053\/1853.0605.v78.n3.32800","article-title":"Ruxolitinib in severe COVID-19: results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome","volume":"78","author":"Iastrebner","year":"2021","journal-title":"Rev. Fac. Cien. Med. Univ. Nac Cordoba"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e30955_bib120","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-023-01979-w","article-title":"The JAK1\/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial","volume":"37","author":"Hammersen","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e30955_bib121","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e30955_bib122","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402406986X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402406986X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:46:14Z","timestamp":1790239574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402406986X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S240584402406986X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30955","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e30955"}}